Vericel Corp (OQ:VCEL)

Jun 11, 2024 08:30 am ET
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist...
May 22, 2024 08:30 am ET
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink...
May 08, 2024 07:55 am ET
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter 2024...
Apr 24, 2024 08:30 am ET
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel’s management...
Feb 29, 2024 07:55 am ET
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2023, and provided...
Feb 27, 2024 08:30 am ET
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen...
Feb 15, 2024 08:30 am ET
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024....
Feb 05, 2024 08:30 am ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The...
Jan 09, 2024 07:55 am ET
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2023....
Jan 03, 2024 08:30 am ET
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference. The...
Nov 08, 2023 07:55 am ET
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2023. Third Quarter 2023...
Nov 07, 2023 08:30 am ET
Vericel to Present at the Stephens Annual Investment Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will present at the Stephens Annual Investment...
Oct 25, 2023 08:30 am ET
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023. Vericel’s...
Sep 28, 2023 08:30 am ET
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the recent publication of results from the Phase 3 DETECT study assessing the safety and efficacy of NexoBrid®...
Sep 20, 2023 04:30 pm ET
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S. commercial availability of NexoBrid® (anacaulase-bcdb) for the removal of eschar in adults with deep...
Sep 06, 2023 08:30 am ET
Vericel to Present at the Morgan Stanley Global Healthcare Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will participate in a fireside chat at the Morgan Stanley 21st Annual...
Aug 02, 2023 07:55 am ET
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2023, and provided updated...
Jul 20, 2023 08:30 am ET
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’s management...
May 10, 2023 07:55 am ET
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2023, and provided updated...
May 02, 2023 09:00 am ET
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor
CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. 
Apr 26, 2023 08:30 am ET
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2023 financial results on Wednesday, May 10, 2023. Vericel’s management...
Feb 28, 2023 08:30 am ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The...
Feb 23, 2023 07:55 am ET
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022, and provided...
Feb 09, 2023 08:00 am ET
Vericel to Report Fourth-Quarter 2022 Financial Results on February 23, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter 2022 financial results on Thursday, February 23, 2023. Vericel’s...
Jan 10, 2023 07:55 am ET
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results for the fourth quarter and year ended December 31, 2022 and an...
Jan 04, 2023 08:34 am ET
Vericel to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference. The...
Dec 29, 2022 01:46 pm ET
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Administration (FDA) has...
Dec 29, 2022 01:45 pm ET
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has approved NexoBrid® (anacaulase-bcdb) for the removal of...
Nov 10, 2022 09:00 am ET
Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health...
Nov 09, 2022 07:55 am ET
Vericel Reports Third Quarter 2022 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2022. Third Quarter 2022...
Oct 26, 2022 08:30 am ET
Vericel to Report Third-Quarter 2022 Financial Results on November 9, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022. Vericel’s...
Sep 22, 2022 08:30 am ET
Vericel to Present at the Ladenburg Thalmann Healthcare Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The...
Sep 06, 2022 08:30 am ET
Vericel to Present at the Morgan Stanley Global Healthcare and H.C. Wainwright Global Investment Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Morgan Stanley and H.C. Wainwright investor conferences....
Aug 03, 2022 07:55 am ET
Vericel Reports Second Quarter 2022 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2022. Second Quarter 2022...
Aug 03, 2022 07:30 am ET
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the U.S. Food and Drug Administration (FDA) has...
Jul 21, 2022 04:05 pm ET
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the publication of results from a retrospective study conducted by the Burn and Reconstructive Centers of...
Jul 20, 2022 08:30 am ET
Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2022 financial results on Wednesday, August 3, 2022. Vericel’s management...
May 04, 2022 07:55 am ET
Vericel Reports First Quarter 2022 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2022. First Quarter 2022...
Apr 20, 2022 08:30 am ET
Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial results and business...
Mar 15, 2022 08:30 am ET
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in...
Mar 01, 2022 08:30 am ET
Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care...
Feb 24, 2022 04:45 pm ET
Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting Officer,...
Feb 24, 2022 07:55 am ET
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2021, and provided...
Feb 10, 2022 09:00 am ET
Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and business...
Feb 02, 2022 04:05 pm ET
Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy...
Jan 04, 2022 08:30 am ET
Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on...
Nov 11, 2021 08:30 am ET
Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and...
Nov 09, 2021 07:40 am ET
Vericel Reports Third Quarter 2021 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2021. Third Quarter...
Oct 21, 2021 08:30 am ET
Vericel to Report Third-Quarter 2021 Financial Results on November 9, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2021 financial results and business...
Sep 08, 2021 08:30 am ET
Vericel to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 13th, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th...
Sep 07, 2021 08:30 am ET
Vericel Expands Executive Leadership Team and Announces Appointment of Patrick Fowler as Senior Vice President, Corporate Development and Strategy
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective today....
Aug 04, 2021 08:00 am ET
Vericel Reports Second Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2021. Second Quarter 2021...
Jul 22, 2021 08:00 am ET
Vericel Corporation Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are...
Jul 21, 2021 08:30 am ET
Vericel to Report Second-Quarter 2021 Financial Results on August 4, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2021 financial results and business...
Jul 18, 2021 10:50 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 15, 2021 08:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL
Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation (“Vericel” or the “Company”) (NASDAQ: VCEL).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 07, 2021 08:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL
Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation (“Vericel” or the “Company”) (NASDAQ: VCEL). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 07, 2021 08:30 am ET
Vericel to Present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann...
Jun 29, 2021 10:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vericel Corporation - VCEL
NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jun 29, 2021 08:45 am ET
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter (CRL) from the U.S. Food...
Jun 29, 2021 08:45 am ET
Vericel Provides Regulatory Update for NexoBrid
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its development partner, MediWound Ltd., received a complete response letter (CRL) from the U.S. Food and...
Jun 09, 2021 09:00 am ET
Vericel to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Goldman Sachs 42nd...
Jun 02, 2021 08:30 am ET
Vericel Announces Appointment of Lisa Wright to Board of Directors
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Lisa Wright to its Board of Directors, effective immediately. Ms. Wright will serve as a...
May 13, 2021 08:30 am ET
Vericel to Present at the Canaccord Genuity Virtual Musculoskeletal Conference on Thursday, May 20, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Canaccord Genuity...
May 05, 2021 07:00 am ET
Vericel Reports First Quarter 2021 Financial Results and Raises Full-Year 2021 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2021. First Quarter 2021...
Apr 21, 2021 08:30 am ET
Vericel to Report First-Quarter 2021 Financial Results on May 5, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2021 financial results and business...
Apr 09, 2021 09:24 am ET
Vericel to Present at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 20th Annual Needham...
Mar 10, 2021 08:30 am ET
Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Oppenheimer 31st Annual...
Mar 02, 2021 08:30 am ET
Vericel Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Joe Mara, Chief Financial Officer, will present the latest company overview at the H.C. Wainwright Virtual...
Feb 24, 2021 08:00 am ET
Vericel Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Full-Year 2021 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2020, and provided...
Feb 22, 2021 08:30 am ET
Vericel to Present at the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the SVB Leerink 10th Annual...
Feb 16, 2021 08:30 am ET
Vericel to Participate in the BTIG Virtual MedTech Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the BTIG...
Feb 12, 2021 08:30 am ET
Vericel Announces Termination of Shareholder Rights Agreement
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board of Directors unanimously approved the termination of the Company’s shareholder rights agreement,...
Feb 10, 2021 08:00 am ET
Vericel to Report Fourth-Quarter 2020 Financial Results on February 24, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2020 financial results and business...
Jan 25, 2021 08:30 am ET
Vericel Announces Appointment of Joe Mara as Chief Financial Officer
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Joe Mara as Chief Financial Officer of the Company, effective today. Mr. Mara joins Vericel with...
Jan 11, 2021 07:15 am ET
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2020 Financial Results and Provides Business Updates
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2020, and provided...
Jan 08, 2021 08:30 am ET
Vericel to Present at the 23rd Annual Needham Growth Conference on Friday, January 15, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 23rd Annual Needham...
Jan 07, 2021 08:30 am ET
Vericel Announces Expansion of MACI Coverage by UnitedHealthcare to Include Patella and Multiple Cartilage Defects in the Knee
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHealthcare has expanded its medical policy for MACI® (autologous cultured chondrocytes on porcine...
Dec 18, 2020 08:30 am ET
Vericel to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 39th Annual J.P. Morgan...
Nov 05, 2020 08:00 am ET
Vericel Reports Record Third Quarter Revenues and Net Income
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2020. Third Quarter 2020...
Nov 02, 2020 08:30 am ET
Vericel to Present at Upcoming Investor Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at the following upcoming investor conferences. The Credit Suisse 29th Annual Healthcare...
Oct 22, 2020 08:30 am ET
Vericel to Report Third-Quarter 2020 Financial Results on November 5, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and business...
Oct 14, 2020 08:00 am ET
Vericel Announces Preliminary Third Quarter 2020 Total Net Revenues of $32 Million
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for the quarter ended September 30, 2020. Preliminary total net revenues...
Oct 09, 2020 08:30 am ET
Vericel To Host Virtual Analyst and Investor Day on October 16, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m. ET. During the event,...
Sep 16, 2020 07:30 am ET
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA)...
Sep 16, 2020 07:30 am ET
Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid® (concentrate of proteolytic enzymes enriched in...
Sep 09, 2020 08:30 am ET
Vericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. The H.C. Wainwright 22nd Annual Global Investment...
Sep 04, 2020 08:30 am ET
Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the 18th Annual Morgan...
Aug 25, 2020 07:00 am ET
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness...
Aug 25, 2020 07:00 am ET
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness...
Aug 05, 2020 08:00 am ET
Vericel Reports Second Quarter 2020 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2020.Second Quarter 2020...
Jul 22, 2020 08:30 am ET
Vericel to Report Second-Quarter 2020 Financial Results on August 5, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2020 financial results and business...
Jul 09, 2020 08:30 am ET
Vericel Announces Preliminary Second Quarter 2020 Financial Results and Provides Business Updates
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary financial results for the quarter ended June 30, 2020, and provided business updates. Preliminary...
Jun 30, 2020 07:00 am ET
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to...
Jun 30, 2020 07:00 am ET
Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns
Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the approval of NexoBrid® (concentrate of proteolytic enzymes enriched in Bromelain)...
May 13, 2020 08:30 am ET
Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the UBS Virtual Global...
May 05, 2020 08:00 am ET
Vericel Reports First Quarter 2020 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2020. First Quarter 2020...
Apr 22, 2020 08:30 am ET
Vericel to Report First-Quarter 2020 Financial Results on May 5, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2020 financial results and business...
Apr 10, 2020 09:00 am ET
Vericel Announces Change to a Virtual Meeting Format For 2020 Annual Meeting of Shareholders
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that as a result of the COVID-19 pandemic, to support the health and well-being of our employees and...
Apr 08, 2020 08:30 am ET
Vericel to Present at the 19th Annual Needham Healthcare Conference on Tuesday, April 14, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 19th Annual Needham...
Apr 02, 2020 09:00 am ET
Vericel Provides Business and Financial Updates
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary unaudited product revenue growth for the quarter ended March 31, 2020, and provided business and...
Feb 25, 2020 08:00 am ET
Vericel Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Full-Year 2020 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2019, and provided...
Feb 24, 2020 10:04 am ET
Vericel to Present at the 40th Annual Cowen Healthcare Conference on Monday, March 2, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 40th Annual Cowen...
Feb 19, 2020 08:00 am ET
Vericel to Present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 9th Annual SVB Leerink...
Feb 11, 2020 08:00 am ET
Vericel to Report Fourth-Quarter 2019 Financial Results on February 25, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2019 financial results and business...
Jan 09, 2020 08:00 am ET
Vericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, CFO, will present a company overview at the 22nd Annual Needham Growth Conference in New...
Jan 06, 2020 06:30 am ET
BARDA Initiates the Procurement of NexoBrid for Emergency Response
MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for Preparedness and...
Jan 06, 2020 06:30 am ET
BARDA Initiates the Procurement of NexoBrid for Emergency Response
MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) within the Assistant Secretary for Preparedness and...
Nov 06, 2019 09:00 am ET
Vericel Announces Appointment of Sean C. Flynn as Vice President and General Counsel
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Sean C. Flynn as Vice President and General Counsel. Mr. Flynn has served as corporate and...
Nov 05, 2019 08:00 am ET
Vericel Reports Record Third Quarter Revenues, Net Income and Operating Cash Flow
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results for the third quarter ended September 30, 2019, and recent business highlights. Third Quarter...
Oct 22, 2019 08:30 am ET
Vericel to Report Third-Quarter 2019 Financial Results on November 5, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2019 financial results and business...
Oct 02, 2019 07:30 am ET
Vericel and MediWound Announce Initiation of U.S. NexoBrid Expanded Access Treatment Protocol
Vericel Corporation (NASDAQ: VCEL) and MediWound Ltd. (NASDAQ: MDWD) today announced initiation of the NexoBrid® expanded access treatment protocol (NEXT) to treat burn patients with deep partial- and full-thickness burns in the U.S. during the...
Sep 27, 2019 08:00 am ET
Vericel to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 Cantor Fitzgerald...
Sep 04, 2019 08:00 am ET
Vericel to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 17th Annual Morgan...
Aug 06, 2019 07:00 am ET
Vericel Reports Second Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results for the second quarter ended June 30, 2019, and recent business highlights. Second Quarter...
Aug 01, 2019 08:00 am ET
Vericel to Present at the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 39th Annual Canaccord...
Jul 23, 2019 08:00 am ET
Vericel to Report Second-Quarter 2019 Financial Results on August 6, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2019 financial results and business...
May 29, 2019 07:30 am ET
BARDA to Fund NexoBrid Expanded Access Treatment Protocol for Thermal Burns
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has agreed to fund the NexoBrid®...
May 15, 2019 08:00 am ET
Vericel to Present at the 2019 UBS Global Healthcare Conference on Wednesday, May 22, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 2019 UBS Global...
May 07, 2019 07:00 am ET
Vericel Reports First Quarter 2019 Financial Results and Raises Full Year 2019 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results for the first quarter ended March 31, 2019, and recent business highlights.First Quarter...
May 07, 2019 02:00 am ET
MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has entered into exclusive license and supply agreements...
May 07, 2019 02:00 am ET
Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has entered into exclusive license and supply agreements with MediWound Ltd. to commercialize...
Apr 25, 2019 08:30 am ET
Vericel to Report First-Quarter 2019 Financial Results on May 7, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2019 financial results and business...
Apr 03, 2019 08:30 am ET
Vericel to Present at Needham Healthcare Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Needham Healthcare...
Apr 01, 2019 08:10 am ET
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ), Digital Turbine, Inc. (NASDAQ:APPS),...
Mar 04, 2019 08:30 am ET
Vericel to Present at Multiple Upcoming Investor Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences. Nick Colangelo, president and CEO will present...
Feb 26, 2019 07:30 am ET
Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2018 and...
Feb 20, 2019 08:30 am ET
Vericel to Participate in Multiple Upcoming Investor Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences. Nick Colangelo, president and CEO and Gerard...
Feb 12, 2019 08:30 am ET
Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2018 financial results and business...
Jan 11, 2019 12:12 pm ET
Vericel to Present at the 21st Annual Needham Growth Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 21st Annual Needham...
Jan 04, 2019 10:00 am ET
Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of outcomes data for 954 burn patients treated with Epicel® (cultured epidermal autografts)...
Dec 14, 2018 07:25 am ET
New Research Coverage Highlights Verisk Analytics, Fortinet, Dine Brands Global, Oppenheimer, Vericel, and Century Communities — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Verisk Analytics, Inc. (NASDAQ:VRSK), Fortinet, Inc. (NASDAQ:FTNT),...
Nov 14, 2018 07:20 am ET
Detailed Research: Economic Perspectives on Plains Group Holdings, Vericel, LGL Group, Bovie Medical, eGain, and Navios Maritime Acquisition — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Plains Group Holdings, L.P. (NYSE:PAGP), Vericel Corporation...
Nov 07, 2018 08:31 am ET
Thinking about buying stock in Advanced Micro Devices, Boxlight Corp., Disney, General Electric or Vericel Corp.?
NEW YORK, Nov. 7, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, BOXL, DIS, GE, and VCEL.
Nov 06, 2018 07:30 am ET
Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2018 and raised its full...
Nov 01, 2018 08:30 am ET
Vericel to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Canaccord Genuity...
Oct 23, 2018 08:30 am ET
Vericel to Report Third-Quarter 2018 Financial Results on November 6, 2018
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2018 financial results and business...
Sep 21, 2018 08:30 am ET
Vericel to Present at Multiple Upcoming Conferences
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences: Nick Colangelo, president and CEO, will present at...
Aug 20, 2018 08:00 am ET
Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer. Dr. Hopper formerly served as Senior...
Aug 06, 2018 04:05 pm ET
Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June 30, 2018. Second Quarter 2018...
Jul 26, 2018 08:30 am ET
Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 38th Annual...
Jul 23, 2018 04:36 pm ET
Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2018 financial results and business...
Jun 25, 2018 08:30 am ET
Vericel Added to Russell 3000® Index
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it has been added to the Russell 3000® Index as part of the annual Russell U.S. Index reconstitution,...
Jun 05, 2018 04:01 pm ET
Vericel Corporation Announces Closing of $74.8 Million Public Offering and Full Exercise of The Underwriters’ Option to Purchase Additional Shares
Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common...
May 31, 2018 08:14 pm ET
Vericel Corporation Prices $65 Million Public Offering of Common Stock
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common...
May 30, 2018 04:01 pm ET
Vericel Corporation Announces Proposed Public Offering of Common Stock
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it intends to offer and sell, subject to market and other conditions, 3,750,000 shares of its common...
May 25, 2018 08:30 am ET
Vericel to Present at the Jefferies 2018 Global Healthcare Conference
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Jefferies 2018...
May 08, 2018 07:00 am ET
Vericel Reports First Quarter 2018 Financial Results
Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the first quarter ended March 31, 2018. First Quarter 2018...
Apr 25, 2018 07:30 am ET
Recent Analysis Shows American Vanguard, Magellan Midstream Partners, Diamondback Energy, Vericel, Air Lease, and Century Communities Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Vanguard Corporation (NYSE:AVD), Magellan Midstream...
Apr 24, 2018 08:00 am ET
Vericel to Report First-Quarter 2018 Financial Results on May 8, 2018
CAMBRIDGE, Mass., April 24, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter...
Apr 10, 2018 09:37 am ET
Vericel to Present at the 6th Annual Cell & Gene Therapy Investor Day
CAMBRIDGE, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...
Mar 23, 2018 08:30 am ET
Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI® (autologous cultured chondrocytes...
Mar 13, 2018 05:00 pm ET
Vericel to Present at the 17th Annual Needham Healthcare Conference
CAMBRIDGE, Mass., March 13, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...
Mar 12, 2018 04:30 pm ET
Vericel to Host Analyst and Investor Day on April 11, 2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an Analyst and Investor Day on...
Mar 09, 2018 08:00 am ET
Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
CAMBRIDGE, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, chief financial officer and VP of corporate...
Mar 05, 2018 07:30 am ET
Vericel Reports Fourth Quarter and Year End 2017 Financial Results and Provides Full Year 2018 Financial Guidance
Record Quarterly Revenues of $23.4 Million Represent a 41% Increase Over Fourth Quarter 2016
Mar 05, 2018 07:00 am ET
Feb 28, 2018 08:10 am ET
Analysis: Positioning to Benefit within Vericel, Eastman Chemical, Monarch Casino & Resort, Brightcove, Carpenter Technology, and Workhorse Group — Research Highlights Growth, Revenue, and Consolidate
NEW YORK, Feb. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vericel Corporation (NASDAQ:VCEL), Eastman Chemical Company...
Feb 26, 2018 08:00 am ET
Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference
CAMBRIDGE, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...
Feb 22, 2018 08:00 am ET
Vericel to Report Fourth-Quarter and Full-Year 2017 Financial Results on March 5, 2018
CAMBRIDGE, Mass., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter...
Feb 05, 2018 08:00 am ET
Vericel to Present at the BIO CEO & Investor Conference
CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...
Feb 01, 2018 08:00 am ET
Vericel to Present at the 7th Annual Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...
Jan 10, 2018 08:00 am ET
Vericel to Present at the 20th Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will...
Jan 03, 2018 07:30 am ET
New Research: Key Drivers of Growth for Vericel, Eastman Chemical, BMC Stock, Alexander & Baldwin, Cal-Maine Foods, and GAIN Capital — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vericel Corporation (NASDAQ:VCEL), Eastman Chemical Company...
Jan 02, 2018 08:00 am ET
Vericel Initiates Collaboration with Innovative Cellular Therapeutics   
CAMBRIDGE, Mass. and SHANGHAI, China, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the initiation of its...
Dec 07, 2017 08:00 am ET
Nov 16, 2017 04:10 pm ET
Vericel to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will...
Nov 07, 2017 07:00 am ET
Vericel Reports Third-Quarter 2017 Financial Results
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016  
Oct 25, 2017 04:30 pm ET
Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:...
Sep 20, 2017 08:00 am ET
Vericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Ladenburg Thalmann 2017 Healthcare Conference at the Sofitel Hotel in New York City on Tuesday, Sept. 26, 2017, at 3:00 p.m. EDT....
Jul 26, 2017 08:00 am ET
Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:...
May 04, 2017 03:20 pm ET
Vericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:...
Feb 27, 2017 04:30 pm ET
Vericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the following investor conferences:...
Feb 21, 2017 07:30 am ET
Vericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has designated the investigation of ixmyelocel‑T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program....
Feb 01, 2017 07:00 am ET
Vericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced the first implant of MACI® (autologous cultured chondrocytes on porcine collagen membrane) in the United States for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults....
Dec 21, 2016 04:05 pm ET
Vericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $20 Million Offering of Common Stock
CAMBRIDGE, Mass., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it has closed its previously announced underwritten public offering of 7,130,000 shares of its common stock at a price to the public of $2.75 per share for gross proceeds of approximately $20 million. The shares include 930,000 shares of common stock sold pursuant to the over-allotment option granted by the Company to the underwriters, which option was exercis...
Dec 15, 2016 06:11 pm ET
Vericel Corporation Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Vericel also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as ...
Nov 22, 2016 08:30 am ET
Vericel to Present at 28th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 28th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City, NY on Wednesday, November 30, 2016, at 1:00pm Eastern time....
Nov 14, 2016 02:00 pm ET
Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel’s Positive Phase 2b ixCELL‑DCM Clinical Trial of Ixmyelocel-T
CAMBRIDGE, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the presentation of additional pre‑specified secondary endpoint results from the ixCELL-DCM trial at the American Heart Association (AHA) Annual Meeting Scientific Sessions.  As previously presented in a late-breaking clinical trial session at the American College of Cardiology’s (ACC) 65th Annual Scientific Session, the ixCELL-DCM trial met its primary endpoint with a 37% re...
Oct 31, 2016 08:00 am ET
Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:...
Sep 26, 2016 08:00 am ET
Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La Jolla, CA on Wednesday, October 5, 2016 at 5:45pm Pacific time....
Sep 21, 2016 08:00 am ET
Vericel to Present at Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Ladenburg Thalmann 2016 Healthcare Conference at Sofitel Hotel in New York City, NY on Tuesday, September 27, 2016, at 11:30am Eastern time....
Sep 12, 2016 08:00 am ET
Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it entered into an expanded term loan and revolving line of credit agreement with Silicon Valley Bank and MidCap Financial Services (MidCap Financial), providing access to up to $20 million of capital to the company to be used for general corporate purposes. As of the quarter ended June 30, 2016, Vericel had an outstanding balance of $2.4 million under an existing agree...
Sep 07, 2016 08:00 am ET
Vericel to Present Data at the American Heart Association’s Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the acceptance of an abstract for presentation at the American Heart Association’s Scientific Sessions 2016 entitled “Reduction in Ventricular Arrhythmias with Ixmyelocel-T: Results from the ixCELL‑DCM Trial”.  The poster will be presented by Timothy Henry, M.D., director of cardiology at Cedars-Sinai Heart Institute, principal investigator of the study, and co-author of the...
Aug 08, 2016 04:05 pm ET
Vericel Reports Second-Quarter 2016 Financial Results
Total Revenues of $12.8 Million Reported for the Quarter...
Aug 01, 2016 07:30 am ET
Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:...
Jul 06, 2016 04:30 pm ET
Vericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and vice president of corporate development, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference at Le Parker Meridien in New York City, NY on Tuesday, July 12, 2016, at 8:30am Eastern time....
Jun 23, 2016 08:00 am ET
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015....
May 10, 2016 07:30 am ET
Vericel Reports First-Quarter 2016 Financial Results
Total Revenues of $14.1 Million Reported for the Quarter...
Apr 27, 2016 04:30 pm ET
Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.